CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Open label peanut OITdrug
Likely dose
Open label peanut OIT 1450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01814241
NCT01814241Phase 2Completed
CompareCT.gov

Mechanisms of Desensitization During Peanut Oral Immunotherapy

University of North Carolina, Chapel Hill·interventional·Posted Mar 19, 2013·Updated Mar 1, 2018

In Brief

A Phase 2 clinical trial evaluating Open label peanut OIT for Food Hypersensitivity. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to attempt to understand how desensitization works in peanut allergic children who are undergoing oral immunotherapy (OIT) to peanut. We want to identify the early changes in the desensitization process the immune cells undergo to become desensitized to the peanut protein.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Hypersensitivity
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 19, 2013
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 13.3 years ago

Interventions

Open label peanut OITdrug

Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.